GlassScriptPhysician profile
David Carlson Roe
NPI 1447214689
$2,442.09
in general payments reported to CMS, 2019-2025
26 companies · $276 in 2025
The $276 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $127 · 2021: $574 · 2022: $458 · 2023: $352 · 2024: $345 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Long Term Medical Supply Or Device Loan: $28.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.83 |
| Long Term Medical Supply Or Device Loan | $28.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $294.30 | 2019-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $282.73 | 2021-2024 | Qelbree, Qelbree |
| Cranial Technologies, INC | $259.36 | 2019-2025 | Doc Band |
| Corium, LLC | $216.78 | 2021-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $214.82 | 2024-2025 | |
| Pfizer INC. | $210.76 | 2019-2025 | |
| Kaleo, INC. | $150.55 | 2019-2024 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $114.45 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $81.22 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $64.22 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $60.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $54.15 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbvie INC. | $52.94 | 2021-2022 | |
| Shire North American Group INC | $48.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.53 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $47.52 | 2020 | |
| Adlon Therapeutics L.P. | $41.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.98 | 2019 | |
| Baxter Healthcare | $28.51 | 2025 | Hillrom - Spot Vision Screener |
| Astrazeneca Pharmaceuticals LP | $25.45 | 2023 | Flumist Quadrivalent |
| Boston Scientific Corporation | $20.93 | 2024 | |
| Arbor Pharmaceuticals, INC. | $20.80 | 2019 | |
| Neos Therapeutics, LP | $17.99 | 2021 | |
| Sanofi Pasteur INC. | $16.90 | 2023 | |
| Vertical Pharmaceuticals, LLC | $16.65 | 2025 | Relexxii |
| Phadia US INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.